Who
Tiago Girao
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Immunovant; Director, Landos Biopharma; VP & Chief Financial Officer, Cerenome.
In numbers
- Trades disclosed
- 42
- Buys
- 3
- Sells
- 3
- Bought
- $33K
- Sold
- $2.8M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 2 Sep 2014
- Last trade
- 23 Jul 2026
- Last filed
- 24 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Jul 2026filed 24 Jul 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Sold | $263K6,798 at $38.69 | filing |
| 23 Jul 2026filed 24 Jul 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Sold | $263K6,798 at $38.69 | filing |
| 26 Jun 2026filed 26 Jun 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Code M | $159K10,000 at $15.90 | filing |
| 26 Jun 2026filed 26 Jun 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Sold | $385K10,000 at $38.46 | filing |
| 26 Jun 2026filed 26 Jun 2026 | IMVT Immunovantoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 26 Jun 2026filed 26 Jun 2026 | IMVT Immunovantoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 26 Jun 2026filed 26 Jun 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Code M | $159K10,000 at $15.90 | filing |
| 26 Jun 2026filed 26 Jun 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Sold | $385K10,000 at $38.46 | filing |
| 23 Apr 2026filed 24 Apr 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Sold | $763K25,760 at $29.62 | filing |
| 23 Apr 2026filed 24 Apr 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Sold | $763K25,760 at $29.62 | filing |
| 7 Apr 2026filed 9 Apr 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Code A | —64,968 at $0.00 | filing |
| 7 Apr 2026filed 9 Apr 2026 | IMVT Immunovantoption or derivative · Biotechnology | SEC FORM 4 Code A | —94,002 at $0.00 | filing |
| 7 Apr 2026filed 9 Apr 2026 | IMVT Immunovantoption or derivative · Biotechnology | SEC FORM 4 Code A | —94,002 at $0.00 | filing |
| 7 Apr 2026filed 9 Apr 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Code A | —64,968 at $0.00 | filing |
| 1 May 2025filed 5 May 2025 | IMVT Immunovantoption or derivative · Biotechnology | SEC FORM 4 Code A | —293,505 at $0.00 | filing |
| 1 May 2025filed 5 May 2025 | IMVT ImmunovantBiotechnology | SEC FORM 4 Code A | —208,388 at $0.00 | filing |
| 23 May 2024filed 23 May 2024 | Landos Biopharmaoption or derivative | SEC FORM 4 Code D | —1,800 | filing |
| 23 May 2024filed 23 May 2024 | Landos Biopharmaoption or derivative | SEC FORM 4 Code D | —1,800 | filing |
| 23 May 2024filed 23 May 2024 | Landos Biopharmaoption or derivative | SEC FORM 4 Code D | —1,800 | filing |
| 23 May 2023filed 24 May 2023 | Landos Biopharmaoption or derivative | SEC FORM 4 Code A | —18,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.